Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license

A Chicago biotech claims in a new lawsuit that Cambridge venture capital firm Third Rock Ventures and bluebird bio CEO Nick Leschly worked to hinder its drug development efforts so it could more easily obtain a key part of its intellectual property. Errant Gene Therapeutics is suing Third Rock Ventures and Leschly three years after it sued New York-based Sloan Kettering Memorial Cancer Center over a stalled rare disease trial. In the lawsuit, filed on Friday in Suffolk County Superior Court, Errant…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news